The safety of temozolomide in the treatment of malignancies

Expert Opinion on Drug Safety

Volumn 8, Issue 4, 2009, Pages 493-499

  Van, Anh Trinh ^a   Patel, Sapna Pradyuman ^a   Hwu, Wen Jen ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Clinical activity; Pharmacology; Safety consideration; Temozolomide

Indexed keywords

CARMUSTINE; DACARBAZINE; METHOTREXATE; PACLITAXEL; PROCARBAZINE; TEMOZOLOMIDE; THALIDOMIDE; TOPOTECAN;

ADJUVANT THERAPY; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BRAIN LYMPHOMA; BRAIN METASTASIS; BREAST CANCER; CANCER RADIOTHERAPY; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; GLIOMA; HUMAN; LEUKEMIA; LOW DRUG DOSE; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; LYMPHOMA; MELANOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA AND VOMITING; NEUTROPENIA; OPPORTUNISTIC INFECTION; REVIEW; T CELL LYMPHOMA; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS, ALKYLATING; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DACARBAZINE; HUMANS; LYMPHOPENIA; NAUSEA; NEOPLASMS; NEUTROPENIA; RADIOTHERAPY; THROMBOCYTOPENIA; VOMITING;

EID: 67650526463     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740330902918281     Document Type: Review

References (43)

1. Stevens MFG, Hickman JA, Langdon SP, et al. Antitumor activity and pharmacokinetics in mice of 8-carbomoyl-3-methyl-imidazo [5,1-d]-1,2,3,5- tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative dacarbazine. Cancer Res 1987;47:5846-52 •• Drug discovery.
2. Newlands ES, Blackledge GRP, Slack JA, et al. Phase I trial of temozolomide (CCRG 81045; M & B 39381: NSC 362856). Br J Cancer 1992;65:287-291
3. Reid JM, Kuffel MJ, Miller JK, et al. Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1. Clin Cancer Res 1999;5(8):2192-2197 (Pubitemid 29399277)
4. 6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 2003;88:1004-11 •• Drug resistance.
5. Schering Corporation. Temodar® Product Information, 2008 •• Drug safety data.
6. Newlands ES, Stevens MF, Wedge SR, et al. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997;23(1):35-61 • Drug developement.
7. Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Can Res 2000;6(7):2585-97 • Temozolomide in gliomas.
8. Agarwala S, Kirkwood JM. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist 2000;5:144-151 (Pubitemid 30238234)
9. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343:1350-4 •• Prognostic and predictive marker of gliomas.
10. Hegi ME, Diserens AC, Gorlia T, et al. MGMT Gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003 •• Predictive biomarker for temozolomide.
11. Middleton MR, Lunn JM, Morris C, et al. O6-Methylguanine-DNA methyltransferase in pretreatment tumor biopsies as a predictor of response to temozolomide in melanoma. Br J Cancer 1998;78(9):1199-1202 (Pubitemid 28479151)
12. 6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide. Br J Cancer 1994;69(3):452-456
13. 6-alkylguanine-DNA alkyltransferase with twice daily oral temozolomide (SCH 52365) in patients with advanced cancer [abstract]. Proc Am Soc Clin Oncol 1996;15:178a
14. Brock CS, Newlands ES, Wedge SR, et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 1998;58(19):4363-4367 (Pubitemid 28450038)
15. Patel M, McCully C, Godwin K, et al. Plasma and cerebrospinal fluid pharmacokinetics of temozolomide [abstract]. Proc Am Soc Clin Oncol 1995;14:1485a
16. Accessed from: http://www.cancer.gov/cancertopics/druginfo/fda- temozolomide
17. Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol 1999;17(9):2762-71 •• Study led to the FDA approval of temozolomide for brain tumor.
18. Stupp R, Dietrich P-Y, Ostermann Kraljevic S, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002;20(5):1375-1382 (Pubitemid 34177445)
19. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96 •• Study led to a new standard therapy for GBM.
20. Yung WKA, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000;83:588-593 (Pubitemid 30636298)
21. Hart MG, Grant R, Garside R, et al. Temozolomide for high grade glioma. Cochrane Database Syst Rev 2008;4:CD007415
22. Estlin EJ, Lashford L, Ablett S, et al. Phase I study of temozolomide in pediatric patients with advanced cancer. Br J Cancer 1998;78:652-61 • Safety data in pediatric patients.
23. Nicholson HS, Krailo M, Ames MM, et al. Phase I study of temozolomide in children and adolescents with recurrent solid tumors: A Report from the Children's Cancer Group. J Clin Oncol 1998;16:3037-43 • Safety data in pediatric patients.
24. Carter CA, Waud WR, Plowman J. Responses of human melanoma, ovarian, and colon tumor xenografts in nude mice to oral temozolomide [abstract]. Proc Am Assoc Cancer Res 1994;35:297
25. Hwu WJ, Ayala AE, Hernandez IM. Alternative temozolomide dosing regimens and novel combinations for the treatment of advanced metastatic melanoma. Onc Rev 2008;2:168-78 •• Various dosing schedules.
26. Bleehen NM, Newlands ES, Lee SM, et al. Cancer research campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 1995;13(4):910-913
27. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18(1):158-66 •• First randomized study comparing temozolomide with DTIC.
28. Patel PM, Suciu S, Mortier L, et al. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV malignant melanoma: final results of the randomized phase III study (EORTC 18032) [abstract]. Ann Oncol 2008;19(Suppl 8):649
29. Dziadziuszko R, Ardizzoni A, Postmus PE, et al. Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases: a phase II study of the EORTC Lung Cancer Group (08965). Eur J Cancer 2003;39:1271-1276 (Pubitemid 36579199)
30. Kouroussis C, Vamvakas L, Vardakis N, et al. Continuous administration of daily low-dose temozolomide in pretreated patients with advanced non-small cell lung cancer: A phase II study. Oncology 2009;76:112-117
31. Raizer JJ, Hwu WJ, Panageas KS, et al. Brain and lepto meningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuro Oncol 2008;10:199-207
32. Paul MJ, Summers Y, Calvert AH, et al. Effect of temozolomide in central nervous system relapse in patients with advanced melanoma. Melanoma Res 2002;12:175-8 • Potential CNS prophylaxis by temozolomide.
33. Agarwala SS, Kirkwood JM, Gore M, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 2004;22(11):2101-2107 (Pubitemid 41095143)
34. Hwu WJ, Lis E, Menell JH, et al. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. Cancer 2005;103:2590-2597 (Pubitemid 40800539)
35. Addeo R, De Rosa C, Faiola V, et al. Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for non-small cell lung cancer and breast cancer patients with brain metastases. Cancer 2008;113:2524-2531
36. Tani M, Fina M, Alinari L, et al. Phase II trial of temozolomide in patients with pretreated cutaneous T-cell lymphoma. Haematologica 2005;90(9):1283-1284 (Pubitemid 41375293)
37. Omuro AM, Taillandier L, Chino O, et al. Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. J Neurooncol 2007;85(2):207-211 (Pubitemid 47629402)
38. Dario A, Tomei G. The safety of the temozolomide in patients with malignant glioma. Curr Drug Saf 2006;1:205-22 • Drug safety data.
39. Su YB, Sohn S, Krown SE, et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol 2004;22(4):610-6 • Lymphopenia and opportunistic infection.
40. Wick W, Weller M. How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience. J Clin Oncol 2005;23(18):4235-4236 (Pubitemid 46211332)
41. Athanassiou H, Synodinou M, Maragoudakis E, et al. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol 2005;23:2372-2377 (Pubitemid 46218731)
42. Sampson JH, Archer GE, Villavicencio AT, et al. Treatment of neoplastic meningitis with intrathecal temozolomide. Clin Cancer Res 1999;5:1183-1188 (Pubitemid 29233236)
43. Heimberger AB, Archer GE, McLendon RE, et al. Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats. Clin Cancer Res 2000;6:4148-4153 (Pubitemid 30807112)